Wilms' tumor: Past, present and (possibly) future

Expert Review of Anticancer Therapy

Volumn 6, Issue 2, 2006, Pages 249-258

  Spreafico, Filippo ^a   Bellani, Franca Fossati ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Nephroblastoma; Prognostic factors; Recurrent Wilms' tumor; Treatment; Wilms' tumor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MYELOABLATIVE AGENT; TOPOTECAN; VINCRISTINE; WT1 PROTEIN;

CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MOLECULAR BIOLOGY; NEPHRECTOMY; NEPHROBLASTOMA; REVIEW; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGE; CHILD; KIDNEY TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRESCHOOL CHILD; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL;

AGE FACTORS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; WILMS TUMOR;

EID: 33644871032     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.2.249     Document Type: Review

References (80)

1. Green DM, Breslow NE, Beckwithg JB et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms tumour: a report from the National Wilms Tumor Study Group. J. Clin. Oncol. 16, 3744-3751 (1998).
2. Green DM, Breslow NE, Beckwith JB et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J. Clin. Oncol. 16, 237-245 (1998).
3. Green DM. The treatment of stages I-IV favourable histology Wilms' tumor. J. Clin. Oncol. 22, 1366-1372 (2004).
4. Tournade MF, Com-Nougué C, de Kraker J et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J. Clin. Oncol. 19, 488-500 (2001).
5. de Kraker J, Graf N, van Tinteren H et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 364, 1229-1235 (2004).
6. Neville HL, Ritchey ML. Wilms' tumor. Overview of the National Wilms' Tumor Study Group results. Urol. Clin. North Am. 27, 435-442 (2000).
7. D'Angio GJ. Pre- or post-operative treatment for Wilms tumor? Who, what, when, where, how, why-and which. Med. Pediatr. Oncol. 41, 545-549 (2003).
8. Kalapurakal JA, Dome JS, Perlman E et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol. 5, 37-46 (2004).
9. Pritchard-Jones K. Controversies and advances in the management of Wilms' tumour. Arch. Dis. Child. 87, 241-244 (2002).
10. Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms's tumor. Urol. Clin. North Am. 27, 443-454 (2000).
11. Pein F, Michon J, Valteau-Couanet D et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J. Clin. Oncol. 16, 3295-3301 (1998).
12. Abu-Ghosh AM, Krailo MD, Goldman SC et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann. Oncol. 13, 460-469 (2002).
13. Dome JS, Liu T, Krasin M et al. Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J. Ped. Hematol. Oncol. 24, 192-198 (2002).
14. Kremens B, Gruhn B, Klingebiel T et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transpl. 30, 893-898 (2002).
15. Campbell AD, Cohn SL, Reynolds M et al. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J. Clin. Oncol. 22, 2885-2890 (2004).
16. Malogolowkin MH, Green DM, Cotton C et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D and doxorubicin. A report from the National Wilms Tumor Study (NWTS) Group. ASCO. FL, USA, 13-17 May (2005) (Abstract 8507).
17. Faria P, Beckwith JB, Mishra K et al. Focal versus diffuse anaplasia in Wilms tumor - new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am. J. Surg. Pathol. 20, 909-920 (1996).
18. Beckwith JB. New developments in the pathology of Wilms tumor. Cancer Invest. 15, 153-162 (1997).
19. Green DM, Beckwith BJ, Breslow NE et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J. Clin. Oncol. 12, 2126-2131 (1994).
20. Beckwith JB, Zuppan CE, Browning NG, Moksness J, Breslow NE. Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Med. Pediatr. Oncol. 27, 422-428 (1996).
21. Bardeesy N, Falkoff D, Petruzzi MJ et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genet. 7, 91-97 (1994).
22. Beniers AJ, Efferth T, Fuzesi L et al. p53 expression in Wilms' tumor: a possible role as prognostic factor. Int. J. Oncol. 18, 133-139 (2001).
23. Argani P, Ladanyi M. Recent advances in pediatric renal neoplasia. Adv. Anat. Pathol. 10, 243-260 (2003).
24. Argani P, Perlman E, Breslow NE et al. Clear cell sarcoma of the kidney. A review of 351 cases from the National Wilms Tumor Study Group pathology center. Am. J. Surg. Pathol. 24, 4-18 (2000).
25. Vujani GM, Sandstedt B, Harms D et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med. Pediatr. Oncol. 38, 79-82 (2002).
26. Weirich A, Leuschner I, Harms D et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann. Oncol. 12, 311-319 (2001).
27. Bergeron C, Graf N, van Tinteren H et al. From results of SIOP-nephroblastoma-93-01 study to SIOP nephroblastoma 2001 study. Med. Pediatr. Oncol. 41(4), 289 (2003) (Abstract O131).
28. Dome JS, Coppes MJ. Recent advances in Wilms tumor genetics. Curr. Opin. Pediatr. 14, 5-11 (2002).
29. Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60, 509-520 (1990).
30. Gessler M, Poustka A, Gavenee W et al. Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. Nature 343, 774-778 (1990).
31. Bonetta L, Kuehn SE, Huang A et al. Wilms' tumor locus on 11p13 defined by multiple CpG islands-associated transcripts. Science 250, 994-997 (1990).
32. Koufos A, Grundy P, Morgan K et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am. J. Hum. Genet. 44, 711-719 (1989).
33. Mannens M, Slater RM, Heyting C et al. Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumors. Hum. Genet. 81, 41-48 (1988).
34. Reeve AE, Sih SA, Raizis AM et al. Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells. Mol. Cell Biol. 9, 1799-1803 (1989).
35. Perotti D, Testi MA, Mondini P et al. Refinement within single yeast artificial chromosome clones of a minimal region commonly deleted on the short arm of chromosome 7 in wilms tumors. Genes Chromosomes Cancer 31, 42-47 (2001).
36. Miozzo M, Perotti D, Minoletti F et al. Mapping of a putative tumor suppressor locus to proximal 7p in Wilms tumors. Genomics 37, 310-315 (1996).
37. Grundy PE, Telzerow PE, Breslow N et al. Loss of heterozigosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res. 54, 2331-2333 (1994).
38. Grundy RG, Pritchard J, Scambler P, Cowell JK. Loss of heterozygosity for the short arm of chromosome 16 in sporadic Wilms tumour. Br. J. Cancer 78, 1181-1187 (1998)
39. Klamt B, Schulze M, Thäte C et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters. Genes Chromosomes Cancer 22, 287-294 (1998).
40. Bown N, Cotterill SJ, Roberts P et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med. Ped. Oncol. 38, 11-21 (2002).
41. Grundy PE, Breslow NE, Li S et al. Loss of heterozigosity for chromosomes 1p and 16q is an adverse prognostic factor in favourable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J. Clin. Oncol. 23, 7312-7321 (2005).
42. Yeh A, Wei M, Golub SB, Yamashiro DJ, Murty VV, Tycko B. Chromosome arm 16q in Wilms tumors: unbalanced chromosomal translocations, loss of heterozigosity, and assessment of the CTCF gene. Genes Chromosomes Cancer 35, 156-163 (2002).
43. Dome JS, Chung S, Bergemann T et al. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res. 59, 4301-4307 (1999).
44. Green DM, Breslow NE, Beckwith JB, Takashima J, Kelalis P, D'Angio GJ. Treatment outcomes in patients less than 2 years of age with small, stage I, favourable-histology Wilms' tumors: a report from the National Wilms' Tumor Study. J. Clin. Oncol. 11, 91-95 (1993).
45. Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, Hutton C, Mitchell C. Old age is an adverse prognostic factor in Stage I, favourable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilms' tumor working group. J. Clin. Oncol. 21, 3269-3275 (2003).
46. Pein F, Tournade MF, Zucker JM et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor - a Phase II study by the French Society of Pediatric Oncology. J. Clin. Oncol. 12, 931-936 (1994).
47. D'Angio GJ, Evans AE, Breslow N et al. The treatment of Wilms' tumor: results of the National Wilms' Tumor Study. Cancer 38, 633-646 (1976).
48. D'Angio GJ, Evans A, Breslow N et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 47, 2302-2311 (1981).
49. D'Angio GJ, Breslow N, Beckwith B et al. Treatment of Wilms tumor. Results of the Third National Wilms Tumor Study. Cancer 64, 349-360 (1989).
50. Green DM, Breslow NE, Evans I, Moksness J, D'Angio GJ. Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. Med. Pediatr. Oncol. 26, 147-152 (1996).
51. Meisel JA, Guthrie KA, Breslow NE et al. Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group. Int. J. Radiat. Oncol. Biol. Phys. 44, 579-585 (1999).
52. Tournade MF, Com-Nougué C, Voûte PA et al. Results of the Sixth International Society of Pediatric Oncology Wilms' tumor trial and study: a risk-adapted therapeutic approach in Wilms' tumor. J. Clin. Oncol. 11, 1014-1023 (1993).
53. Jereb B, Burgers MV, Tournade MF et al. Radiotherapy in the SIOP (International Society of Paediatric Oncology) nephroblastoma studies: a review. Med. Pediatr. Oncol. 22, 221-227 (1994).
54. Lemerle J, Voûte PA, Tournade MF et al. Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms' tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Pediatric Oncology (SIOP). Cancer 38, 647-654 (1976).
55. Lemerle J, Voûte PA, Tournade MF et al. Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J. Clin. Oncol. 1, 604-609 (1983).
56. Pritchard J, Imeson J, Barnes J et al. Results of the United Kingdom Children's Cancer Study Group first Wilms tumour study. J. Clin. Oncol. 13, 124-133 (1995).
57. Mitchell C, Morris-Jones P, Kelsey A et al. The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms tumour study. Br. J. Cancer 83, 602-608 (2000).
58. Mitchell C, Shannon R, Vujanic et al. The treatment of Wilms tumour: the United Kingdom Children's Cancer Study Group Third Wilms' tumour study. Med. Pediatr. Oncol. 41, 287 (2003) (Abstract O119).
59. Pritchard-Jones K, Mitchell C, Shannon R, Middleton H, Walker J, Gornall P. Reasons for non-randomisation in the UK3 trial of surgical approach in localized Wilms tumour requiring a difficult day one randomisation. A UKCCSG Wilms tumour group study. Med. Pediatr. Oncol. 41, 257 (2003) (Abstract O001).
60. Spreafico F, Terenziani M, Piva L et al. Wilms tumor (WT): 2nd Italian co-operative study CNR/AIEOP92, final results. Med. Pediatr. Oncol. 39, 370 (2002) (Abstract P373).
61. Vujanic GM, Kelsey A, Mitchell C Shannon RS, Gornall P. The role of biopsy in the diagnosis of renal tumors of childhood: results of the UKCCSG Wilms tumor study 3. Med. Pediatr. Oncol. 40, 18-22 (2003).
62. Ehrlich PF, Ritchey ML, Hamilton TE et al. Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5. J. Ped. Surg. 40, 208-213 (2005).
63. Othersen HB, Delorimier A, Hrabovsky E et al. Surgical evaluation of lymph node metastases in Wilms tumor. J. Pediatr. Surg. 25, 330-331 (1990).
64. Shamberger RC, Guthrie KA, Ritchey ML et al. Surgergery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann. Surgery 229, 292-297 (1999).
65. Spreafico F, Gandola L, Terenziani M et al. Radical regional lymph node (LN) dissection can avoid irradiation in stage III node-positive Wilms tumor (WT) patients? Pediatr. Blood Cancer 45(4), 386 (2005) (Abstract O014).
66. Ritchey ML, Shamberger RC, Haase G et al. Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group. J. Am. Coll. Surg. 192, 63-68 (2001).
67. Godzinski J, Tournade MF, deKraker J et al. Rarity of surgical complications after postchemotherapy nephrectomy for nephroblastoma. Experience of the International Society of Paediatric Oncology Trial and Study 'SIOP-9'. International Society of Paediatric Oncology Nephroblastoma Trial and Study Committee. Eur. J. Pediatr. Surg. 8, 83-86 (1998).
68. Ritchey M, Broecker B. Surgical complications following nephrectomy for Wilms tumor. Med. Pediatr. Oncol. 41, 251 (2003) (Abstract S027).
69. Green DM, Beckwith JB, Weeks DA, Moksness J, Breslow NE, D'Angio GJ. The relationship between microsubstaging variables, age at diagnosis, and tumor weight of children with stage I/favourable histology Wilms' tumor. Cancer 74, 1817-1820 (1994).
70. Larsen E, Perez-Atayde A, Green DM, Retik A, Clavell LA, Sallan SE. Surgery only for the treatment of patients with stage I (Cassady) Wilms' tumor. Cancer 66, 264-266 (1990).
71. Green DM, Breslow NE, Beckwith B et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J. Clin. Oncol. 19, 3719-3724 (2001).
72. Shamberger R, Grundy P, Green D. Nephrectomy only for very low risk Wilms tumor (VLRWT). Pediatr. Blood Cancer 45(4), 379 (2005) (Abstract SL061).
73. Grundy P, Breslow N, Green DM et al. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J. Clin. Oncol. 7, 638-647 (1989).
74. Miser JS, Tournade MF. The management of relapsed Wilms tumor. Hematol. Oncol. Clin. North Am. 9, 1287-1302 (1995).
75. Dome J, Geoffrey N, Ashley Hill D et al. Antitumor activity of topotecan against Wilms tumor: translation of a xenograft model to a Phase II study. Pediatr. Blood Cancer 45(4), 432 (2005) (Abstract PA033).
76. Breslow NE, Ou SS, Haase GM et al. Doxorubicin for favorable histology, stage II-III Wilms tumor. Results from the National Wilms Tumor Studies. Cancer 101, 1072-1080 (2004).
77. Green DM, Grigoriev YA, Nan B et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J. Clin. Oncol. 19, 1926-1934 (2001).
78. Pachnis A, Pritchard J, Gaze M, Levitt G, Michalski A. Radiotherapy omitted in the treatment of selected children under 3 years of age with stage III favorable histology Wilms tumor. Med. Pediatr. Oncol. 31, 150-152 (1998).
79. Grundy RG, Hutton C, Middleton H et al. Outcome of patients with stage III or inoperable WT treated on the Second United Kingdom Children's Cancer Study Group (UKCCSG) Study. Pediatr. Blood Cancer 42, 311-319 (2004).
80. Baez F, Fossati Bellani F, Ocampo E et al. Treatment of childhood Wilms' tumor without radiotherapy in Nicaragua. Ann. Oncol. 13, 944-948 (2002).